HOOKIPA Pharma Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
HOOK Company Description
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
HOOK Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view HOOK Smart Score
Score Breakdown
HOOK Company Description
Show More
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies. Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of HOOK by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by HOOK's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on HOOK's company Twitter account
WallStreetBets
Number of mentions of HOOK in WallStreetBets Daily Discussion
HOOK News
Recent insights relating to HOOK
CNBC Recommendations
Recent picks made for HOOK stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in HOOK
Corporate Flights
Flights by private jets registered to HOOK
Our Analysis